The correlation between fetal hemoglobin and outcome in non-Hodgkin's lymphoma [1]

International Journal of Biological Markers

Volumn 19, Issue 2, 2004, Pages 168-169

  Wolk, Moshe ^a,b   Newlands, E S ^a  

^a CHARING CROSS HOSPITAL   (United Kingdom)

^b MINISTRY OF HEALTH   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOGLOBIN F;

CALCULATION; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; FISHER EXACT TEST; HEMAGGLUTINATION INHIBITION TEST; HEMOGLOBIN DETERMINATION; HEMOGLOBINOPATHY; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; NONHODGKIN LYMPHOMA; PREDICTION; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; FETAL HEMOGLOBIN; HEMATOLOGIC TESTS; HUMANS; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

MARTES PENNANTI;

EID: 4243068618     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (8)

1. Miles DK, Freedman MH, Stephens K, et al. Patterns of hematopoietic lineage. Involvement in children with neurofibromatosis type 1 and malignant myeloid disorders. Blood 1996; 88: 4314-20.
2. Sires UI, Mallory SB, Hess JL, et al. Cutaneous presentation of juvenile chronic myelogenous leukemia: A diagnostic and therapeutic dilemma. Pediatr Dermatol 1995; 12: 364-8.
3. Rautonen J, Marti AS. Initial blood fetal hemoglobin concentration is elevated and is associated with prognosis in children with acute lymphoid or myeloid leukemia. Blut 1990; 61: 17-20.
4. Wolk M, Kieselstein M, Ben-Dor CG, Brufman G. Fetal hemoglobin screening in whole blood and in plasma of cancer patients. Tumour Biol 1991; 12: 45-51.
5. Wolk M, Newland AC, De la Salle B, et al. Refinement of plasma fetal hemoglobin (HbF) measurements, as related to whole blood HbF, in cancer patients. J Tumor Marker Oncol 1999; 14: 115-26.
6. Wolk M, Martin JE, Constantin R. Blood cells with fetal haemoglobin (F-cells) detected by immunohistochemistry as indicators of solid tumors. J Clin Pathol 2004 (accepted for publication).
7. Carr BI, Rahbar S, Doroshow JH, et al. Fetal hemoglobin gene activation in a phase II study of 5,6-dihydro-5-azacytidine for bronchogenic carcinoma. Cancer Res 1987; 47: 4199-201.
8. Wolk M, Kieselstein M, Brufman G. Evaluation of fetal hemoglobin in various malignancies with reference to the patients' age. Tumour Biol 1988; 9: 95-100.